Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. (Q53525799)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. |
scientific article |
Statements
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. (English)
1 reference
M Kaufmann
1 reference
E Bajetta
1 reference
L Y Dirix
1 reference
L E Fein
1 reference
S E Jones
1 reference
N Zilembo
1 reference
J L Dugardyn
1 reference
C Nasurdi
1 reference
R G Mennel
1 reference
J Cervek
1 reference
C Fowst
1 reference
A Polli
1 reference
E di Salle
1 reference
A Arkhipov
1 reference
G Piscitelli
1 reference
L L Miller
1 reference
G Massimini
1 reference
1 April 2000
1 reference
18
1 reference
1399-1411
1 reference
7
1 reference
Identifiers
1 reference